Mandate

Vinge advises Bygghemma in connection with the acquisition of Outl1.se

July 26, 2019 M&A

Vinge has advised Bygghemma Sverige AB in connection with the acquisition of 51 per cent of the shares in Outl1.se with an option to acquire the remaining 49 per cent within 3-4 years.

Bygghemma Group is the leading online supplier of home improvement products in the Nordic region. Bygghemma Group had a turnover of approximately SEK 5 billion in 2018, its head office is situated in Malmö and the company is listed on Nasdaq Stockholm. Outl1.se is a leading online actor in Sweden within the home, household and leisure products sector and in the last five years has demonstrated an average annual growth of 67 per cent and had a turnover of approximately SEK 100 million in 2018. Outl1.se will be consolidated within Bygghemma Group’s DIY segment.

Vinge’s team consisted of partner Kristian Ford together with, among others, associates Philip Åberg, Tilda Hall, Jessica Salomonsson and Daniel Melander Björner (employment law).
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024